| Date Filed | Type | Description |
| 10/04/2023 |
4
| Cross Shawn (CEO & Chair of the Board) has filed a Form 4 on Applied Molecular Transport Inc.|
Txns:
| Sold 3,293 shares
@ $0.2412, valued at
$794.3
Sold 536 shares
@ $0.2404, valued at
$128.9
Sold 477 shares
@ $0.2402, valued at
$114.6
Sold 1,253 shares
@ $0.2075, valued at
$260 |
|
| 10/02/2023 |
4
| Cross Shawn (CEO & Chair of the Board) has filed a Form 4 on Applied Molecular Transport Inc.|
Txns:
| Granted 886,111 shares
@ $0
Sold 193,960 shares
@ $0.1585, valued at
$30.7k
|
|
| 03/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/06/2022 |
4
| Cross Shawn (President & COO) has filed a Form 4 on Applied Molecular Transport Inc.|
Txns:
| Sold 468 shares
@ $1.4203, valued at
$664.7
Sold 416 shares
@ $1.4199, valued at
$590.7 |
|
| 06/03/2022 |
4
| Cross Shawn (President & COO) has filed a Form 4 on Applied Molecular Transport Inc.|
Txns:
| Sold 1,767 shares
@ $2.9679, valued at
$5.2k
Sold 2,166 shares
@ $3.0425, valued at
$6.6k
|
|
| 05/18/2022 |
4
| Cross Shawn (President & COO) has filed a Form 4 on Applied Molecular Transport Inc.|
Txns:
| Granted 18,000 shares
@ $0
Granted 84,000 options to buy
@ $3.99, valued at
$335.2k
|
|
| 02/16/2022 |
4
| Cross Shawn (CFO) has filed a Form 4 on Applied Molecular Transport Inc.|
Txns:
| Granted 20,250 shares
@ $0
Granted 94,500 options to buy
@ $8.29, valued at
$783.4k
|
|
| 01/06/2022 |
4
| Cross Shawn (CFO) has filed a Form 4 on Applied Molecular Transport Inc.|
Txns:
| Granted 31,500 shares
@ $0 |
|
| 12/02/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 08/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/04/2020 |
3
| Cross Shawn (CFO) has filed a Form 3 on Applied Molecular Transport Inc. |
| 03/16/2018 |
3
| Cross Shawn (CEO) has filed a Form 3 on GT Biopharma, Inc. |